Carlina Develops Anticancer Nanocapsules For Pets And Patients
This article was originally published in The Pink Sheet Daily
French drug delivery firm Carlina is developing new lipid-based nanoparticle formulations of cancer drugs for pets and patients, and aims to build a proprietary pipeline with the help of collaborations with other companies.
You may also be interested in...
Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.